Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 2;117(1):9. doi: 10.1007/s00395-022-00919-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Similars regulate fibrotic mRNA signalling. a RNA isolated from HCF treated with bufalin, buf-s-5, buf-s-13, buf-s-14, buf-s-17, buf-s-18, lycorine or lyco-s was analysed using the nanoString Fibrosis panel. Out of 770 mRNAs measured, expression of 369 genes was significantly deregulated and distinct expression profiles for the compound groups bufalin-like (blue) or lycorine-like (red) were obtained. n = 3 biological replicates (donors). Analysed with multiple t tests (p < 0.05), adjusted following BY. b 93 genes were up-regulated, respectively, downregulated in all bufalin-like compound-treated HCF, and further 13 genes in at least 5 of the 6 different treatments. c buf-s-14 and buf-s-18 tended to increase overall expression, whereas the number of significantly up- and down-regulated genes was similar after treatment with lyco-s. d Pathway signatures were scored by average expression of genes in respective pathway, normalized to respective signature mean. Bufalin and its similars have nearly interchangeable pathway profiles, whereas the profile of lycorine is similar to controls. Treatment with lyco-s is the only condition with reduction in collagen, ECM and EMT pathways. e Average expression per gene for selected pathways. n = 3 biological replicates (donors)